Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Mentice AB is a leading provider of medical simulation solutions, with a primary focus on improving endovascular therapies. The company's products enhance the training and performance of healthcare professionals by providing realistic, high-fidelity simulation environments. Mentice AB's offerings play a critical role in medical education and the ongoing skill development of surgeons and interventionalists, allowing them to hone their skills in a risk-free setting before transitioning to real-life procedures. Mentice AB impacts various sectors within healthcare, notably the cardiovascular and interventional radiology fields. By supplying technologically advanced simulators, Mentice aids in shortening the learning curve for complex procedures and helps medical professionals keep pace with rapid advancements in endovascular technologies. The company is headquartered in Gothenburg, Sweden, and operates globally, contributing significantly to the advancement of medical training standards. Their simulations are used by hospitals, medical device companies, and academic institutions worldwide, underscoring Mentice AB's significant role in enhancing patient safety and procedure efficacy in the healthcare market.
kr 1.13
+kr 0.00 (+0.00%)
Live · 10:45 PM · Twelve Data
The business is unprofitable at the operating level (-11.26% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 3.9% YoY. Margins deteriorated 7.0pp alongside, both lines moving the wrong way.
Free cash flow declined 2514% versus the prior year, cash generation momentum has weakened. ROIC dropped from -6.10% to -16.13%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 287M
▼ -3.9% YoY
Net Income (TTM)
-kr 21M
▼ -75.5% YoY
Op. Margin
-6.07%
▼ -7.0pp YoY
ROIC
-16.13%
▼ -10.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 5M
▼ -2514.3% YoY
Op. Cash Flow (TTM)
kr 10M
▼ -1208.1% YoY
Net Debt
-kr 17M
Net Cash Position
Cash & Equiv.
kr 33M
3Y CAGR: +8.6%
Continue Research
Mentice AB (MNTC.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Mentice AB scores 36/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Mentice AB scores 36 out of 100 on Intrinsiqq's quality score, passing 2 of 6 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -6.1% operating margin and a -16.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh MNTC.XSTO's valuation and scores 36/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.